---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-23-000077"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T21:34:35.298210+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health CSO/COO Ryan Phan resigns, transitions to advisor

## Summary
- Dr. Ryan Phan resigns as Chief Scientific & Operating Officer effective Sept 15, 2023, becomes advisor Sept 16, 2023.
- Consulting agreement pays $20,000/month through Jan 15, 2024; options continue vesting during term.
- $50,000 retention bonus forgiven if Phan remains employed through Dec 31, 2023.
- Phan to continue as CLIA lab medical director until Jan 15, 2024.

## SEC filing metadata
- accession: 0000926617-23-000077
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661723000077/0000926617-23-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661723000077/awh-20230907x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-23-000077
- JSON: https://secwatch.observer/filing/0000926617-23-000077.json
- Plain text: https://secwatch.observer/filing/0000926617-23-000077.txt

## Key facts
- Executive change
  Ryan Phan resigned as Chief Scientific and Operating Officer at Aspira Women's Health Inc..
  - Action: resigned
  - Role: Chief Scientific and Operating Officer
  source text: On August 3, 2023, Dr. Ryan Phan, the Chief Scientific and Operating Officer of Aspira Women’s Health Inc., (the “Company), notified the Company that he will resign from these roles with the Company effective September 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000077/0000926617-23-000077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.